This pharma stock is gearing up for a huge surge

After years of a slowdown in performance and revenue, Eli Lilly (NYSE: LLY) is starting to turn the page. With its innovations in the pharmaceutical sector, most notably in diabetes treatment, its medications performed well, raking in a huge chunk of revenue and propelling this pharmaceutical giant to the 10th largest company by market cap.Eli Lilly’s latest pharmaceutical product for diabetes and obesity, Mounjaro (marketed as Zepbound for weight management), is anticipated to potentially emerge as the hig ...